Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:03PM EDT
After hours:
| Previous Close | 105.92 |
| Open | 106.23 |
| Bid | 106.44 x 800 |
| Ask | 106.52 x 800 |
| Day's Range | 105.52 - 106.53 |
| 52 Week Range | 82.73 - 115.49 |
| Volume | |
| Avg. Volume | 8,818,146 |
| Market Cap | 269.741B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 38.42 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.92 (2.76%) |
| Ex-Dividend Date | Mar 14, 2023 |
| 1y Target Est | N/A |
- Business Wire
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
- Business Wire
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
- Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
© 2023 Yahoo. All rights reserved.
